Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 501–600 of 2,576
Inhibition and Modulation of γ-Secretase for Alzheimer's Disease
Wolfe, M. S. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.010 · Cited by 143
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials
Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt213 · Cited by 142
“All ADAD mutations in APP, PSEN1, and PSEN2 result in an increase in the production of Aβ species or in the Aβ42/40 ratio [37,38], providing very strong support for the amyloid hypothesis in AD.”
BackgroundGoulay, R., Romo, L. M., Hol, E. M., & Dijkhuizen, R. M. (2019) · Translational Stroke Research · doi:10.1007/s12975-019-00755-2 · Cited by 159
Alzheimer's Disease and the Amyloid β Protein: What Is the Role of Amyloid ?
Small, D. H., & McLean, C. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730443.x · Cited by 143
Calcium Responses in Fibroblasts from Asymptomatic Members of Alzheimer's Disease Families
Etcheberrigaray, R., Hirashima, N., Nee, L., Prince, J., Govoni, S., Racchi, M., Tanzi, R. E., & Alkon, D. L. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0176 · Cited by 141
“…cellular and molecular level (Baker et al., 1988; Peterson et al., 1988; Govoni et al., 1993; McCoy et al., 1993; Scott, 1993; Etcheberrigaray et al., 1993, 1994; Huang et al., 1994, 1995; Ito et al., 1994; Kim et al., 1995; Gibson et al., 1996a,b; Hirashima et al., 1996; Scheuner et al., 1996).”
BackgroundSelf-citationPresenilins: molecular switches between proteolysis and signal transduction
Annaert, W. G., & Strooper, B. D. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01455-1 · Cited by 158
Subcellular Distribution and Turnover of Presenilins in Transfected Cells
Zhang, J., Kang, D. E., Xia, W., Okochi, M., Mori, H., Selkoe, D. J., & Koo, E. H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12436 · Cited by 146
Self-citationMannose receptor is present in a functional state in rat microglial cells
Marzolo, M. P., von Bernhardi, R., & Inestrosa, N. C. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991101)58:3<387::aid-jnr4>3.0.co;2-l · Cited by 64
Alzheimer’s Disease as Proteolytic Disorders: Anabolism and Catabolism of β-Amyloid
Saido, T. C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00033-5 · Cited by 156
Current Concepts in the Pathogenesis of Alzheimer’s Disease
Carr, D. B., Goate, A., Phil, D., & Morris, J. C. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00262-3 · Cited by 159
Pellegrini, L., Passer, B. J., Tabaton, M., Ganjei, J. K., & D'Adamio, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21011 · Cited by 139
Activation and intrinsic γ-secretase activity of presenilin 1
Ahn, K., Shelton, C. C., Tian, Y., Zhang, X., Gilchrist, M. L., Sisodia, S. S., & Li, Y.-M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013246107 · Cited by 139
Neve, R. L., McPhie, D. L., & Chen, Y. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02869-9 · Cited by 165
Pinnix, I., Musunuru, U., Tun, H., Sridharan, A., Golde, T., Eckman, C., Ziani-Cherif, C., Onstead, L., & Sambamurti, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005968200 · Cited by 140
Self-citationTienari, P. J., Ida, N., Ikonen, E., Simons, M., Weidemann, A., Multhaup, G., Masters, C. L., Dotti, C. G., & Beyreuther, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.4125 · Cited by 139
Biochemistry and Molecular Biology of Amyloid β‐Protein and the Mechanism of Alzheimer's Disease
(2008) · Handbook of Clinical Neurology · doi:10.1016/s0072-9752(07)01223-7 · Cited by 137
Self-citationTwenty years of Alzheimer’s disease‐causing mutations
Goate, A., & Hardy, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07575.x · Cited by 137
“…1–3 have been largely borne out (Citron et al. 1992; Haass et al. 1992; Mullan et al. 1992; Seubert et al. 1992; Cai et al. 1993; Suzuki et al. 1994; Scheuner et al. 1996), and the identification of presenilins as the other genes involved in the Mendelian disorder (St George-Hyslop and Petit 2005)…”
BackgroundSelf-citationVanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., & Van der Linden, A. (2005) · Magnetic Resonance in Medicine · doi:10.1002/mrm.20385 · Cited by 138
Mutant Presenilin-1 Induces Apoptosis and Downregulates Akt/PKB
Weihl, C. C., Ghadge, G. D., Kennedy, S. G., Hay, N., Miller, R. J., & Roos, R. P. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-13-05360.1999 · Cited by 137
“Although compelling evidence links PS mutations to abnormal amyloid precursor processing and b-amyloid deposition (Scheuner et al., 1996), little is known about how PS mutations result in the hyperphosphorylation of microtuble-associated protein tau, a pathological hallmark of AD.”
BackgroundHartmann, D., Strooper, B. D., & Säftig, P. (1999) · Current Biology · doi:10.1016/s0960-9822(99)80331-5 · Cited by 151
“Missense mutations of the human PS1 gene are a major cause of familial Alzheimer’s disease [4], leading to an increased production of the long, strongly amyloidogenic form of the β-A4 amyloid peptide from the amyloid precursor protein (APP) [9–12].”
Chyung, A. S. C., Greenberg, B. D., Cook, D. G., Doms, R. W., & Lee, V. M.-Y. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.138.3.671 · Cited by 114
“There is now strong evidence that mutations in both the APP gene and the recently identified presenilin genes cause AD by altering APP processing in ways that lead to the production of more amyloidogenic form of Ab (i.e., Ab42; Scheuner et al., 1996).”
Plasma amyloid beta measurements - a desired but elusive Alzheimer's disease biomarker
Toledo, J. B., Shaw, L. M., & Trojanowski, J. Q. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt162 · Cited by 133
Smith, I. F., Green, K. N., & LaFerla, F. M. (2005) · Cell Calcium · doi:10.1016/j.ceca.2005.06.021 · Cited by 148
Sato, N., Urano, F., Leem, J. Y., Kim, S., Li, M., Donoviel, D. B., Bernstein, A., Lee, A. S., Ron, D., Veselits, M., et al. (2000) · Nature Cell Biology · doi:10.1038/35046500 · Cited by 144
Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease
Hauptmann, S., Keil, U., Scherping, I., Bonert, A., Eckert, A., & Müller, W. E. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.03.012 · Cited by 146
Désiré, L., Bourdin, J., Loiseau, N., Peillon, H., Picard, V., De Oliveira, C., Bachelot, F., Leblond, B., Taverne, T., Beausoleil, E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507913200 · Cited by 135
Making the final cut: Pathogenic amyloid-β peptide generation by γ-secretase
Steiner, H., Fukumori, A., Tagami, S., & Okochi, M. (2018) · Cell Stress · doi:10.15698/cst2018.11.162 · Cited by 133
“Although it had already been shown shortly after the discovery of presenilins that the mutations change the Aβ42/40 ratio [15], the mechanism(s) behind this phenomenon has remained obscure for a long time and only recently become more clear.”
BackgroundThe Future of Precision Medicine in the Cure of Alzheimer’s Disease
Arafah, A., Khatoon, S., Rasool, I., Khan, A., Rather, M. A., Abujabal, K. A., Faqih, Y. A. H., Rashid, H., Rashid, S. M., Bilal Ahmad, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020335 · Cited by 133
Siman, R., Reaume, A. G., Savage, M. J., Trusko, S., Lin, Y.-G., Scott, R. W., & Flood, D. G. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-23-08717.2000 · Cited by 133
“It is supported by findings that all of the FAD-linked mutations examined so far increase selectively the production or concentration of Ab42 (Citron et al., 1992; Cai et al., 1993; Suzuki et al., 1994; Borchelt et al., 1996; 1997; Duff et al., 1996; Scheuner et al., 1996; Oyama et al., 1998).”
Plasma Amyloid-β as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging
Lui, J. K., for the AIBL Research Group, Laws, S. M., Li, Q.-X., Villemagne, V. L., Ames, D., Brown, B., Bush, A. I., De Ruyck, K., Dromey, J., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-090249 · Cited by 134
“ed in the existing literature [6,7,18–30,33].”
ResultPathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 154
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 133
Widespread Changes in Dendritic Spines in a Model of Alzheimer's Disease
Knafo, S., Alonso-Nanclares, L., Gonzalez-Soriano, J., Merino-Serrais, P., Fernaud-Espinosa, I., Ferrer, I., & DeFelipe, J. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn111 · Cited by 132
“Mice The mouse line used in this study (N = 9, age 12--14 months) expressed a Mo/Hu APP695swe construct in conjunction with the exon-9--deleted variant of human presenilin 1 (PS1-dE9) (Scheuner et al. 1996).”
MethodThe Role of Presenilins in γ-Secretase Activity
Wolfe, M. S., & Haass, C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r000026200 · Cited by 132
Cai, D., Leem, J. Y., Greenfield, J. P., Wang, P., Kim, B. S., Wang, R., Lopes, K. O., Kim, S.-H., Zheng, H., Greengard, P., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209065200 · Cited by 118
Protein misfolding in Alzheimer’s and Parkinson’s disease: genetics and molecular mechanisms
Forloni, G., Terreni, L., Bertani, I., Fogliarino, S., Invernizzi, R. W., Assini, A., Ribizzi, G., Negro, A., Calabrese, E., Volonté, M. A., et al. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00076-3 · Cited by 150
Davis, J. A., Naruse, S., Chen, H., Eckman, C., Younkin, S., Price, D. L., Borchelt, D. R., Sisodia, S. S., & Wong, P. C. (1998) · Neuron · doi:10.1016/s0896-6273(00)80998-8 · Cited by 131
Self-citationFAD mutant PS-1 gene-targeted mice: increased Aβ42 and Aβ deposition without APP overproduction
Flood, D. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00330-x · Cited by 131
β-Amyloid (Aβ) Deposition in the Brains of Aged Orangutans
Gearing, M., Tigges, J., Mori, H., & Mirra, S. S. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00012-2 · Cited by 130
Wiltfang, J., Smirnov, A., Schnierstein, B., Kelemen, G., Matthies, U., Klafki, H., Staufenbiel, M., Hüther, G., Rüther, E., & Kornhuber, J. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150180332 · Cited by 130
Arendash, G. W., Gordon, M. N., Diamond, D. M., Austin, L. A., Hatcher, J. M., Jantzen, P., DiCarlo, G., Wilcock, D., & Morgan, D. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717604 · Cited by 130
Alzheimer‐associated presenilin‐2 confers increased sensitivity to poptosis in PC12 cells
Deng, G., Pike, C. J., & Cotman, C. W. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01142-8 · Cited by 131
Collins, J. S., Perry, R. T., Watson, B., Harrell, L. E., Acton, R. T., Blacker, D., Albert, M. S., Tanzi, R. E., Bassett, S. S., McInnis, M. G., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001204)96:6<823::aid-ajmg26>3.0.co;2-i · Cited by 129
“…et al., 1992], and presenillin 2 (PS2) on chromosome 1 [Levy-Lahad et al., 1995], are proposed to cause AD by increasing the production of Ab42 [Scheuner et al., 1996; Selkoe, 1996; Citron et al., 1997], which aggregates [Jarrett and Lansbury, 1993] to form neurotoxic AD plaques [Yankner et…”
BackgroundSelf-citationGómez-Isla, T., Growdon, W. B., McNamara, M. J., Nochlin, D., Bird, T. D., Arango, J. C., Lopera, F., Kosik, K. S., Lantos, P. L., Cairns, N. J., et al. (1999) · Brain · doi:10.1093/brain/122.9.1709 · Cited by 131
Self-citationTreatment Strategies Targeting Amyloid -Protein
Schenk, D., Basi, G. S., & Pangalos, M. N. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006387 · Cited by 126
“…caveat of current mouse models in the context of therapeutics targeting production of amyloid is that, in contrast to rare familial forms of AD (Scheuner et al. 1996), there is limited evidence that sporadic AD is a driven by overproduction of Ab (Fukumoto et al. 2002; Holsinger et al. 2002;…”
BackgroundBlood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Alzheimer disease: Amyloidogenesis, the presenilins and animal models
Newman, M., Musgrave, I., & Lardelli, M. T. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.12.001 · Cited by 157
Wirths, O., Multhaup, G., Czech, C., Feldmann, N., Blanchard, V., Tremp, G., Beyreuther, K., Pradier, L., & Bayer, T. A. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00442.x · Cited by 125
Hua, X., Lei, M., Zhang, Y., Ding, J., Qun-ying, H., Hu, G., & Xiao, M. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.02.030 · Cited by 126
Kukar, T., Prescott, S., Eriksen, J. L., Holloway, V., Murphy, M. P., Koo, E. H., Golde, T. E., & Nicolle, M. M. (2007) · BMC Neuroscience · doi:10.1186/1471-2202-8-54 · Cited by 128
“In humans, AD-causing mutations in APP and PS elevate plasma Aβ42 levels by 30%–100%, and are associated with the onset of dementia in the 3rd to 5th decade of life [6].”
Neuronal death in Alzheimer’s disease and therapeutic opportunities
Donev, R., Kolev, M., Millet, B., & Thome, J. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00889.x · Cited by 126
“In AD patients carrying missense mutations on either of the genes for PS1 or PS2, it was reported that the overall levels of A peptides were increased in the plasma, and that levels of the more amyloidogenic A 42 were increased in cultured fibroblasts of patients carrying inherited mutations on the genes for presenili…”
BackgroundPresenilins: Members of the γ-Secretase Quartets, But Part-Time Soloists Too
Wakabayashi, T., & De Strooper, B. (2008) · Physiology · doi:10.1152/physiol.00009.2008 · Cited by 123
The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Guo, Q., Sebastian, L., Sopher, B. L., Miller, M. W., Glazner, G. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.4125 · Cited by 125
Okochi, M., Tagami, S., Yanagida, K., Takami, M., Kodama, T. S., Mori, K., Nakayama, T., Ihara, Y., & Takeda, M. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.11.028 · Cited by 123
“However, because even small elevations in the ratio of Ab42(43) to total Ab (Ab42[43] ratio) in secreted Ab by PS or bAPP mutations trigger familial AD (Kuperstein et al., 2010; Scheuner et al., 1996; Suzuki et al., 1994), the proteolysis is regulated strictly in this aspect.”
BackgroundBroersen, K., Jonckheere, W., Rozenski, J., Vandersteen, A., Pauwels, K., Pastore, A., Rousseau, F., & Schymkowitz, J. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzr020 · Cited by 126
“…in the gene encoding for the independent composites of the g-secretase complex all induce the formation of longer Ab peptides, which appear to be directly involved in plaque formation in the brains of Alzheimer’s disease patients (Jarrett et al., 1993; Suzuki et al., 1994; Scheuner et al., 1996).”
BackgroundMudher, A., Chapman, S., Richardson, J., Asuni, A., Gibb, G., Pollard, C., Killick, R., Iqbal, T., Raymond, L., Varndell, I., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-04987.2001 · Cited by 121
“Mutations in the APP gene and the presenilin genes, associated with familial AD, result in increased production of total Ab or relatively more of the longer Ab42 (Borchelt et al., 1996; Scheuner et al., 1996 ), and recent evidence suggests that the presenilins either have or are tightly coupled to g-secretase activity…”
BackgroundSequence Determinants of Enhanced Amyloidogenicity of Alzheimer Aβ42 Peptide Relative to Aβ40
Kim, W., & Hecht, M. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505763200 · Cited by 123
Interaction of Presenilins with the Filamin Family of Actin-Binding Proteins
Zhang, W., Han, S. W., McKeel, D. W., Goate, A., & Wu, J. Y. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-03-00914.1998 · Cited by 123
Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease
Gurney, M. E., D'Amato, E. C., & Burgin, A. B. (2015) · Neurotherapeutics · doi:10.1007/s13311-014-0309-7 · Cited by 121
Kinetic characterization of amyloid-beta 1–42 aggregation with a multimethodological approach
Bartolini, M., Naldi, M., Fiori, J., Valle, F., Biscarini, F., Nicolau, D. V., & Andrisano, V. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2011.03.020 · Cited by 118
Rice, J. P., Goate, A., Williams, J. T., Bierut, L., Dorr, D., Wu, W., Shears, S., Gopalakrishnan, G., Edenberg, H. J., Foroud, T., et al. (1997) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19970531)74:3<247::aid-ajmg3>3.0.co;2-n · Cited by 209
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 120
Huitrón‐Reséndiz, S., Sánchez-Alavez, M., Gallegos, R. A., Berg, G. I., Crawford, E. F., Giacchino, J. L., Games, D., Henriksen, S. J., & Criado, J. R. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03373-x · Cited by 130
Morishima-Kawashima, M., Oshima, N., Ogata, H., Yamaguchi, H., Yoshimura, M., Sugihara, S., & Ihara, Y. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64847-x · Cited by 119
Mahairaki, V., Ryu, J., Peters, A., Chang, Q., Li, T., Park, T. S., Burridge, P. W., Talbot, C. C., Asnaghi, L., Martin, L. J., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0511 · Cited by 122
Kimura, N. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040503 · Cited by 118
“Importantly, most FAD-related mutations selectively increase the production of longer Aβ, Aβ42, which is prone to aggregate more readily than the dominant Aβ40 species [52–54].”
BackgroundNew clues to Alzheimer's disease: Unraveling the roles of amyloid and tau
Yanker, B. A. (1996) · Nature Medicine · doi:10.1038/nm0896-850 · Cited by 136
Plasma amyloid β, apolipoprotein E, lacunar infarcts, and white matter lesions
Van Dijk, E. J., Prins, N. D., Vermeer, S. E., Hofman, A., Van Duijn, C. M., Koudstaal, P. J., & Breteler, M. M. B. (2004) · Annals of Neurology · doi:10.1002/ana.20050 · Cited by 120
Notch Receptors, Partners and Regulators: From Conserved Domains to Powerful Functions
Egan, S. E., St-Pierre, B., & Leow, C. C. (1998) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-80481-6_11 · Cited by 144
Sayre, L. M., Zagorski, M. G., Surewicz, W. K., Krafft, G. A., & Perry, G. (1997) · Chemical Research in Toxicology · doi:10.1021/tx970009n · Cited by 118
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118
The vascular contribution to Alzheimer's disease
Altman, R., & Rutledge, J. C. (2010) · Clinical Science · doi:10.1042/cs20100094 · Cited by 93
In Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric Disorders
Pantazopoulos, H., & Berretta, S. (2016) · Neural Plasticity · doi:10.1155/2016/9847696 · Cited by 119
Wolfe, M. S. (2009) · Chemical Reviews · doi:10.1021/cr8004197 · Cited by 132
Yogev-Falach, M., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2003) · The FASEB Journal · doi:10.1096/fj.03-0078fje · Cited by 118
Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years
Mondadori, C. R. A., Buchmann, A., Mustovic, H., Schmidt, C. F., Boesiger, P., Nitsch, R. M., Hock, C., Streffer, J., & Henke, K. (2006) · Brain · doi:10.1093/brain/awl266 · Cited by 120
“On the cellular level, pathogenic PSEN1 mutations modify amyloid precursor protein processing, thereby leading to an enhanced amyloid beta 42 secretion (Scheuner et al., 1996).”
BackgroundJanicki, S., & Monteiro, M. J. (1997) · The Journal of Cell Biology · doi:10.1083/jcb.139.2.485 · Cited by 118
“…patients with mutations in presenilin genes and transgenic mice express- ing mutant human PS genes have elevated levels of Ab42-43 peptides (Duff et al., 1996; Scheuner et al., 1996; Borchelt et al., 1996; Tomita et al., 1997), which have been documented to induce apoptosis (LaFerla et al., 1995).”
Quintero-Monzon, O., Martin, M. M., Fernandez, M. A., Cappello, C. A., Krzysiak, A. J., Osenkowski, P., & Wolfe, M. S. (2011) · Biochemistry · doi:10.1021/bi2007146 · Cited by 118
Structure and Function of the γ-Secretase Complex
Wolfe, M. S. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00401 · Cited by 116
Histone Acetylation Modifiers in the Pathogenesis of Alzheimer’s Disease
Lu, X., Wang, L., Yu, C., Yu, D., & Yu, G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00226 · Cited by 113
“PS1 is the catalytic core component of γ-secretase, one of the sequential cleavage enzymes to APP, and mainly produces the neurotoxic Aβ peptides that are responsible for neuronal degeneration and cognitive dysfunction in AD (Scheuner et al., 1996).”
BackgroundThe role of intracellular amyloid β in Alzheimer's disease
Li, M., Chen, L., Lee, D. H. S., Yu, L., & Zhang, Y. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.08.002 · Cited by 135
Alzheimer's disease: β‐Amyloid protein and tau
Morishima‐Kawashima, M., & Ihara, Y. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10355 · Cited by 116
“…so far identified, as well as an unidentified gene on chromosome 10, are all associated with increased A 42 production or its enhanced deposition in the brain (Suzuki et al., 1994; Scheuner et al., 1996; Borchelt et al., 1996; Morishima-Kawashima et al., 2000; Ertekin-Taner et al., 2000; Table I).”
BackgroundShinohara, M., Fujioka, S., Murray, M. E., Wojtas, A., Baker, M., Rovelet-Lecrux, A., Rademakers, R., Das, P., Parisi, J. E., Graff-Radford, N. R., et al. (2014) · Brain · doi:10.1093/brain/awu046 · Cited by 115
“It is well known that almost all familial Alzheimer’s dis- ease-linked genetic mutations upregulate the cellular production of amyloid-b42, or increase the ratio of amyloid-b42 to amyloidb40 (Citron et al., 1992; Duff et al., 1996; Scheuner et al., 1996).”
BackgroundBasun, H., Bogdanovic, N., Ingelsson, M., Almkvist, O., Näslund, J., Axelman, K., Bird, T. D., Nochlin, D., Schellenberg, G. D., Wahlund, L.-O., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.499 · Cited by 115
“Also, PS1 and PS2 mutations result in elevated A levels as has been demonstrated both in vivo and in vitro.(5,6) The convergence of AD mutations toward APP metabolism has been explained by the identification of presenilin as an essential component of the complex that mediates secretase cleavage.”
BackgroundSelf-citationRegional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 115
“Disease-causing mutations in the three genes that lead to autosomal dominant Alzheimer’s disease have been shown to promote the formation of the putatively neurotoxic form of amyloid-b , a peptide of 42 amino acids (Suzuki et al. , 1994; Scheuner et al. , 1996; Gomez-Isla et al. , 1999).”
BackgroundMilojevic, J., Esposito, V., Das, R., & Melacini, G. (2007) · Journal of the American Chemical Society · doi:10.1021/ja067367+ · Cited by 117
Zhou, L., Brouwers, N., Benilova, I., Vandersteen, A., Mercken, M., Van Laere, K., Van Damme, P., Demedts, D., Van Leuven, F., Sleegers, K., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100138 · Cited by 109
“…production, but most affect the ratio of different Ab peptides without increasing total Ab, favouring a relative increase in Ab42 versus other species (Bentahir et al, 2006; Citron et al, 1992; De Jonghe et al, 2001; Di Fede et al, 2009; Kwok et al, 2000; Scheuner et al, 1996; Suzuki et al, 1994).”
BackgroundCleavage Agents for Soluble Oligomers of Amyloid β Peptides
Suh, J., Yoo, S. H., Kim, M. G., Jeong, K., Ahn, J. Y., Kim, M., Chae, P. S., Lee, T. Y., Lee, J., Lee, J., et al. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200702399 · Cited by 114
On the role of sidechain size and charge in the aggregation of A β 42 with familial mutations
Yang, X., Meisl, G., Frohm, B., Thulin, E., Knowles, T. P. J., & Linse, S. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803539115 · Cited by 129
Mohmmad Abdul, H., Sultana, R., Keller, J. N., St. Clair, D. K., Markesbery, W. R., & Butterfield, D. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03647.x · Cited by 114
“Mutations in presenilins cause most early onset FAD cases and similarly increase amyloid peptides (Borchelt et al. 1996; Scheuner et al. 1996).”
Parent, A., Linden, D. J., Sisodia, S. S., & Borchelt, D. R. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0207 · Cited by 116
Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models
Levites, Y., Smithson, L. A., Price, R. W., Dakin, R. S., Yuan, B., Sierks, M. R., Kim, J., McGowan, E., Kim Reed, D., Rosenberry, T. L., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-6463fje · Cited by 116
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
Kanwar, J., Sriramoju, & Kanwar (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30919 · Cited by 108
“Mutations in amyloid precursor protein allow enhanced proteolysis by the β-amyloid precursor protein-cleaving enzyme (β-secretase), followed by increased production of insoluble Aβ plaques by γ-secretases.(23) These Aβ plaques aggregate readily, remaining a focus for generation of disease and tend to be the real culpr…”
BackgroundThe Neurodegenerative Mitochondriopathies
Swerdlow, R. H. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1095 · Cited by 112
“Mutations in the amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2) genes cause autosomal dominant AD and appear to alter processing of APP towards the 42 amino acid beta amyloid (Aβ) derivative [45].”
BackgroundFukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., & Yanagisawa, K. (2000) · European Neurology · doi:10.1159/000008156 · Cited by 113
“In CSF from familial AD patients carrying the V717I-amyloid precursor protein (APP) mutation and presenilin (PS) mutations [ ,”
BackgroundAppearance of Sodium Dodecyl Sulfate-Stable Amyloid β-Protein (Aβ) Dimer in the Cortex During Aging
Enya, M., Morishima-Kawashima, M., Yoshimura, M., Shinkai, Y., Kusui, K., Khan, K., Games, D., Schenk, D., Sugihara, S., Yamaguchi, H., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65273-x · Cited by 111
The Genetics of Alzheimer’s Disease
Barber, R. C. (2012) · Scientifica · doi:10.6064/2012/246210 · Cited by 101
“�inding the remaining genetic factors that contribute to the development of late onset Alzheimer’s disease holds the potential to provide novel targets for treatment and prevention, leading to the development of effective strategies to combat this devastating disease.”
BackgroundThe neuronal endosomal-lysosomal system in Alzheimer's disease
Nixon, R. A., Mathews, P. M., & Cataldo, A. M. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3114 · Cited by 111
“Although the normal biological function(s) of the multi-membrane spanning PS1 protein remains unknown, FAD-causing mutations are known to increase the intracellular production of Aβ142/43 relative to Aβ1-40 peptide in cell lines, transgenic animals, and humans [6,21,30,87], and recent data suggest that presenilin (PS)…”
Background
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.